Bone morphogenetic protein use in spine surgery—complications and outcomes: a systematic review
- 1.1k Downloads
Because of significant complications related to the use of autologous bone grafts in spinal fusion surgery, bone substitutes and growth factors such as bone morphogenetic protein (BMP) have been developed. One of them, recombinant human (rh) BMP-2, has been approved by the Food and Drug Administration (FDA) for use under precise conditions. However, rhBMP-2-related side effects have been reported, used in FDA-approved procedures, but also in off-label use.A systematic review of clinical data was conducted to analyse the rhBMP-2-related adverse events (AEs), in order to assess their prevalence and the associated surgery practices.
Medline search with keywords “bone morphogenetic protein 2”, “lumbar spine”, “anterolateral interbody fusion” (ALIF) and the filter “clinical trial”. FDA published reports were also included. Study assessment was made by authors (experienced spine surgeons), based on quality of study designs and level of evidence.
Extensive review of randomised controlled trials (RCTs) and controlled series published up to the present point, reveal no evidence of a significant increase of AEs related to rhBMP-2 use during ALIF surgeries, provided that it is used following FDA guidelines. Two additional RCTs performed with rhBMP-2 in combination with allogenic bone dowels reported increased bone remodelling in BMP-treated patients. This AE was transient and had no consequence on the clinical outcome of the patients. No other BMP-related AEs were reported in these studies.
This literature review confirms that the use of rhBMP-2 following FDA-approved recommendations (i.e. one-level ALIF surgery with an LT-cage) is safe. The rate of complications is low and the AEs had been identified by the FDA during the pre-marketing clinical trials. The clinical efficiency of rhBMP-2 is equal or superior to that of allogenic or autologous bone graft in respect to fusion rate, low back pain disability, patient satisfaction and rate of re-operations. For all other off-label use, the safety and effectiveness of rhBMP-2 have not been established, and further RCTs with high level of evidence are required.
KeywordsBone morphogenetic protein Spinal fusion Osteoinduction Adverse effects
Compliance with ethical standards
Declaration of competing interests
Nothing to disclose for the authors.
- 1.Lavery K, Swain P, Falb D, Alaoui-Ismaili MH (2008) BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem 283(30):20948–20958. doi: 10.1074/jbc.M800850200 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.FDA (2002) InFUSE™ Bone Graft/LT-CAGE™ Lumbar Tapered Fusion Devices—P000058. United States Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=P000058. Accessed 05 Sept 2012
- 15.FDA (2008) FDA public health notification: life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. US FDA. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062000.htm
- 20.Burkus JK, Gornet MF, Schuler TC, Kleeman TJ, Zdeblick TA (2009) Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am 91(5):1181–1189. doi: 10.2106/JBJS.G.01485 CrossRefPubMedGoogle Scholar
- 22.Comer GC, Smith MW, Hurwitz EL, Mitsunaga KA, Kessler R, Carragee EJ (2012) Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study. Spine J 12(10):881–890. doi: 10.1016/j.spinee.2012.09.040 CrossRefPubMedGoogle Scholar
- 25.Pradhan BB, Bae HW, Dawson EG, Patel VV, Delamarter RB (2006) Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 31(10):E277–E284. doi: 10.1097/01.brs.0000216442.12092.01 CrossRefGoogle Scholar
- 30.Moshel YA, Hernandez EI, Kong L, Liu C, Samadani U (2008) Acute renal insufficiency, supraventricular tachycardia, and confusion after recombinant human bone morphogenetic protein-2 implantation for lumbosacral spine fusion. J Neurosurg Spine 8(6):589–593. doi: 10.3171/SPI/2008/8/6/589 CrossRefPubMedGoogle Scholar
- 32.Williams BJ, Smith JS, Fu KM, Hamilton DK, Polly DW Jr, Ames CP, Berven SH, Perra JH, Knapp DR Jr, McCarthy RE, Shaffrey CI (2011) Does BMP increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without BMP. Spine. doi: 10.1097/BRS.0b013e318216d825 Google Scholar
- 35.Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, Kumegawa M, Chihara K (1995) Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 10(11):1681–1690. doi: 10.1002/jbmr.5650101110 CrossRefPubMedGoogle Scholar
- 37.Dimar JR, Glassman SD, Burkus KJ, Carreon LY (2006) Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 31(22):2534–2539. doi: 10.1097/01.brs.0000240715.78657.81, discussion 2540CrossRefGoogle Scholar
- 43.Lykissas MG, Aichmair A, Sama AA, Hughes AP, Lebl DR, Cammisa FP, Girardi FP (2014) Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study. Spine J 14(2):217–224. doi: 10.1016/j.spinee.2013.06.109 CrossRefPubMedGoogle Scholar
- 49.Glassman SD, Dimar JR, Carreon LY, Campbell MJ, Puno RM, Johnson JR (2005) Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine 30(15):1694–1698CrossRefPubMedGoogle Scholar
- 50.Glassman SD, Carreon LY, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, Dimar JR (2008) RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine 33(26):2843–2849. doi: 10.1097/BRS.0b013e318190705d CrossRefPubMedGoogle Scholar
- 51.Dawson E, Bae HW, Burkus JK, Stambough JL, Glassman SD (2009) Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial. J Bone Joint Surg Am 91(7):1604–1613. doi: 10.2106/JBJS.G.01157 CrossRefPubMedGoogle Scholar
- 52.Dimar JR 2nd, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY (2009) Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 91(6):1377–1386. doi: 10.2106/JBJS.H.00200 CrossRefPubMedGoogle Scholar
- 54.Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA (2003) A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 28(12):1219–1224. doi: 10.1097/01.BRS.0000065486.22141.CA, discussion 1225PubMedGoogle Scholar
- 55.Papakostidis C, Kontakis G, Bhandari M, Giannoudis PV (2008) Efficacy of autologous iliac crest bone graft and bone morphogenetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results. Spine (Phila Pa 1976) 33(19):E680–E692. doi: 10.1097/BRS.0b013e3181844eca CrossRefGoogle Scholar
- 59.Winkler S, Niedermair T, Fuchtmeier B, Grifka J, Grassel S, Anders S, Heers G, Wagner F (2015) The impact of hypoxia on mesenchymal progenitor cells of human skeletal tissue in the pathogenesis of heterotopic ossification. Int Orthop 39(12):2495–2501. doi: 10.1007/s00264-015-2995-0 CrossRefPubMedGoogle Scholar
- 61.Mummaneni PV, Pan J, Haid RW, Rodts GE (2004) Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the joint section meeting on disorders of the spine and peripheral nerves, March 2004. J Neurosurg Spine 1(1):19–23. doi: 10.3171/spi.2004.1.1.0019 CrossRefPubMedGoogle Scholar
- 67.Albilia JB, Tenenbaum HC, Clokie CM, Walt DR, Baker GI, Psutka DJ, Backstein D, Peel SA (2013) Serum levels of BMP-2, 4, 7 and AHSG in patients with degenerative joint disease requiring total arthroplasty of the hip and temporomandibular joints. J Orthop Res 31(1):44–52. doi: 10.1002/jor.22182 CrossRefPubMedGoogle Scholar